Evidence map›Paper›PMID 36204453›Full record

ArticleFrontiers in research metrics and analytics2022

Assessing emerging technologies from an arms control perspective.

Maximilian Brackmann, Michèle Gemünden, Cédric Invernizzi, Stefan Mogl

Abstract read
In one paragraph

Article in Frontiers in research metrics and analytics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Maximilian BrackmannNBC Arms Control Staff Unit, Spiez Laboratory, Federal Office for Civil Protection, Spiez, Switzerland.
Michèle GemündenCenter for Security Studies, ETH Zurich, Zurich, Switzerland.
Cédric InvernizziNBC Arms Control Staff Unit, Spiez Laboratory, Federal Office for Civil Protection, Spiez, Switzerland.
Stefan MoglChemistry Division, Spiez Laboratory, Federal Office for Civil Protection, Spiez, Switzerland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Developments in science and technology improve health and wellbeing of humankind, for example with better methods to detect and treat diseases. However, some advances have led to the development of weapons of mass destruction: chemical and biological weapons. Although banned by international treaties, chemical weapons have been used in recent years in assassinations and the Syrian civil war. Additionally, biological weapons became the subject of recent suspicions and allegations. While not limited to these fields, the so-called dual-use potential-the possibility to apply aspects both with benevolent or malevolent intentions-is especially pronounced in the life sciences. Here, we showcase some areas explored at the conference series Spiez CONVERGENCE that facilitates an exchange between science, arms control and international security. Together, these communities discuss the potential impact of life scientific advances on the Chemical and Biological Weapons Conventions. Enabled by digital technologies, DNA sequencing and synthesis provide the toolbox to (re)construct viruses and cells, which demonstrated invaluable during the COVID-19 pandemic but bear the misuse risk to allow intentionally triggering an outbreak. Open databases and algorithms could be used to generate new chemical weapons. We argue that preventing unintended consequences of life science research while promoting its benefits with responsible science, requires awareness and reflection about unexpected risks of everyone involved in the research process. The strength of the ban of chemical and biological weapons also depends on scientists interacting with policy makers in evaluating risks and implementing measures to reduce them.

Indexed as

biological weaponschemical weaponsdual-useresearch of concernscience policysecurity policy

Identifiers

PMID36204453
PMCPMC9531594

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.